Superiority of Ticagrelor Over Clopidogrel in Patients After Cardiac Arrest Undergoing Therapeutic Hypothermia

Canadian Journal of Cardiology

Volumn 30, Issue 11, 2014, Pages 1396-1399

  Moudgil, Rohit ^a   Al Turbak, Haytham ^a   Osborne, Christina ^a   Hibbert, Benjamin ^a   So, Derek Y F ^a   Le May, Michel R ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; TICAGRELOR; ADENOSINE; ANTITHROMBOCYTIC AGENT; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICLOPIDINE;

ADULT; ARTICLE; BLEEDING; BLOOD TRANSFUSION; BRAIN INJURY; CARDIAC PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG FATALITY; FEMALE; HEART ARREST; HUMAN; INDUCED HYPOTHERMIA; LOADING DRUG DOSE; MALE; OPEN STUDY; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PROSPECTIVE STUDY; RETURN OF SPONTANEOUS CIRCULATION; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; FOLLOW UP; METABOLISM; MIDDLE AGED; PROCEDURES; THROMBOCYTE; THROMBOCYTE AGGREGATION; TREATMENT OUTCOME;

ADENOSINE; BLOOD PLATELETS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HEART ARREST; HUMANS; HYPOTHERMIA, INDUCED; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84908474530     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2014.07.745     Document Type: Article

References (18)

1. Tanguay J.F., Bell A.D., Ackman M.L., et al. Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy. Can J Cardiol 2013, 29:1334-1345.
2. Simard T., Hibbert B., Ramirez F.D., et al. The evolution of coronary stents: a brief review. Can J Cardiol 2014, 30:35-45.
3. Penela D., Magaldi M., Fontanals J., et al. Hypothermia in acute coronary syndrome: brain salvage versus stent thrombosis?. JAm Coll Cardiol 2013, 61:686-687.
4. Sambu N., Radhakrishnan A., Dent H., et al. Personalised antiplatelet therapy in stent thrombosis: observations from the Clopidogrel Resistance in Stent Thrombosis (CREST) registry. Heart 2012, 98:706-711.
5. Bjelland T.W., Hjertner O., Klepstad P., et al. Antiplatelet effect of clopidogrel is reduced in patients treated with therapeutic hypothermia after cardiac arrest. Resuscitation 2010, 81:1627-1631.
6. Wallentin L., Becker R.C., Budaj A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. NEngl J Med 2009, 361:1045-1057.
7. Maze R., LeMay M.R., Froeschl M., et al. Endovascular cooling catheter related thrombosis in patients undergoing therapeutic hypothermia for out of hospital cardiac arrest. Resuscitation 2014 Oct, 85(10):1354-1358.
8. Maze R., Le May M.R., Hibbert B., et al. The impact of therapeutic hypothermia as adjunctive therapy in a regional primary PCI program. Resuscitation 2013, 84:460-464.
9. Hibbert B., Maze R., Pourdjabbar A., et al. Acomparative pharmacodynamic study of ticagrelor versus clopidogrel and ticagrelor in patients undergoing primary percutaneous coronary intervention: the CAPITAL RELOAD study. PLoS One 2014, 9:e92078.
10. Hibbert B., MacDougall A., Labinaz M., et al. Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry. Circ Cardiovasc Interv 2012, 5:805-812.
11. Hogberg C., Erlinge D., Braun O.O. Mild hypothermia does not attenuate platelet aggregation and may even increase ADP-stimulated platelet aggregation after clopidogrel treatment. Thromb J 2009, 7:2.
12. Zhou J., Poloyac S.M. The effect of therapeutic hypothermia on drug metabolism and response: cellular mechanisms to organ function. Expert Opin Drug Metab Toxicol 2011, 7:803-816.
13. Fritz H.G., Holzmayr M., Walter B., et al. The effect of mild hypothermia on plasma fentanyl concentration and biotransformation in juvenile pigs. Anesth Analg 2005, 100:996-1002.
14. Vandenbranden M., Wrighton S.A., Ekins S., et al. Alterations of the catalytic activities of drug-metabolizing enzymes in cultures of human liver slices. Drug Metab Dispos 1998, 26:1063-1068.
15. Alexopoulos D., Galati A., Xanthopoulou I., et al. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. JAm Coll Cardiol 2012, 60:193-199.
16. Steg P.G., James S., Harrington R.A., et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 2010, 122:2131-2141.
17. Price M.J., Berger P.B., Teirstein P.S., et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011, 305:1097-1105.
18. Collet J.P., Cuisset T., Range G., et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. NEngl J Med 2012, 367:2100-2109.